What adverse effect is less common with Carboplatin compared to Cisplatin?

Carboplatin is generally associated with lower nephrotoxicity compared to Cisplatin. Cisplatin, a platinum-based chemotherapeutic agent, can cause significant damage to the kidneys, leading to increased creatinine levels and potential renal failure, particularly in individuals with preexisting renal impairment or in settings of dehydration. This is likely due to the way Cisplatin is filtered and excreted by the kidneys, which makes renal toxicity a concern.

In contrast, Carboplatin, which is a derivative of Cisplatin, has a modified structure that results in reduced renal toxicity. While it can still have some effects on renal function, the incidence and severity of kidney damage are notably less than that seen with Cisplatin administration. This difference in nephrotoxicity is significant when considering the overall management of patients undergoing chemotherapy, as it allows for a more favorable side effect profile in terms of kidney health when Carboplatin is selected as the treatment agent.